Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Zai Lab Limited
  6. News
  7. Summary
    ZLAB   US98887Q1040

ZAI LAB LIMITED

(ZLAB)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
45.27 USD   +10.87%
08/03Zai Lab Names Operations Chief
MT
08/03ZAI LAB LTD : Change in Directors or Principal Officers (form 8-K)
AQ
08/03Zai Lab Limited Appoints Joshua Smiley as Chief Operating Officer
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zai Lab, Novocure's Phase 2 Study of Gastric Cancer Combination Therapy Meets Primary Endpoint

06/03/2022 | 09:07am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
NOVOCURE LIMITED 0.99% 75.62 Delayed Quote.0.72%
ZAI LAB LIMITED 10.87% 45.27 Delayed Quote.-27.97%
All news about ZAI LAB LIMITED
08/03Zai Lab Names Operations Chief
MT
08/03ZAI LAB LTD : Change in Directors or Principal Officers (form 8-K)
AQ
08/03Zai Lab Limited Appoints Joshua Smiley as Chief Operating Officer
CI
07/27SEC Chair Stresses Need to Reach Audit Deal With Chinese Regulators
MT
07/26China’s Securities Watchdog Denies Plan to Help Firms Avoid US Delisting
MT
07/20Deal to Avoid Delisting of 200 Firms in US Bourses Remains Unclear
MT
07/19Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022
GL
07/18SECTOR UPDATE : Health Care Stocks Extending Monday Slide
MT
07/18Zai Lab Rises After Joining Two Stock Connect Programs
MT
07/18SECTOR UPDATE : Health Care Stocks Sinking in Monday Trading
MT
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Financials (USD)
Sales 2022 224 M - -
Net income 2022 -441 M - -
Net cash 2022 828 M - -
P/E ratio 2022 -9,96x
Yield 2022 -
Capitalization 4 431 M 4 431 M -
EV / Sales 2022 16,1x
EV / Sales 2023 7,74x
Nbr of Employees 1 951
Free-Float 99,8%
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 45,27 $
Average target price 101,05 $
Spread / Average Target 123%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Joshua L. Smiley Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED-27.97%4 431
CSL LIMITED2.07%98 543
SAMSUNG BIOLOGICS CO.,LTD.-0.89%48 860
WUXI BIOLOGICS (CAYMAN) INC.-19.88%40 273
BIOGEN INC.-9.05%31 664
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-19.97%23 596